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Chemical pleurodesisAbstract Background: The most common primary malignant tumor of the pleura is malignant
mesothelioma. It is a highly aggressive tumor that has become a very important issue over recent
years. Evidence suggests that EGFR is involved in the pathogenesis and progression of different
carcinomas.
Aim of the work: To study the role of EGFR in MPM and to investigate its value for successful
chemical pleurodesis.
Patients and Methods: This study included 53 patients with exudative pleural effusion. All were
subjected to full history taking, clinical examination, CT chest, pleural biopsy histopathological
analysis and EGFR Ab immunostaining. According to pleural biopsy histopathology, the patient
population was divided into 3 subgroups; subgroup I (19 patients diagnosed benign pleural
effusion); subgroup II (21 patients diagnosed MPM) and subgroup III (13 patients diagnosed
malignant pleural effusion other than MPM).
Results: Regarding comparison between the 3 subgroups in the demographic data, there was no
statistically signiﬁcant difference in age, sex and smoking prevalence. Regarding pleural ﬂuid
analysis, there was no statistically signiﬁcant difference in protein and LDH levels but there was
874 A. El-Hosainy et al.statistical signiﬁcance in sugar levels between subgroups I and II. There was statistical signiﬁcance
regarding predominant cell pattern during pleural ﬂuid cytology. Also there was statistical
signiﬁcance regarding immunostaining for the detection of EGFR in pleural biopsy among study
subgroups. However, there was no statistical signiﬁcance regarding comparison between success
of chemical pleurodesis and expression of EGFR among malignant subgroups of pleural effusion.
Conclusion: There is evidence that EGFR is frequently overexpressed in MPM and therefore
may be used as a potential therapeutic target.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.Introduction
The most common primary malignant tumor of the pleura is
malignant mesothelioma. It arises from mesothelial surfaces
of the pleural and peritoneal cavities, as well as from the tunica
vaginalis and pericardium [1].
Malignant pleural mesothelioma is a highly aggressive
tumor that has become a very important issue over recent
years [2].
Epidermal growth factor receptor exists on the cell surface
and is activated by binding of its speciﬁc ligands, including epi-
dermal growth factor and others [3]. The resulting signaling
network initiates diverse cellular pathways leading to prolifer-
ation, migration, gene transcription, cell cycle progression and
cell survival [4].
Evidence suggests that the EGFR is involved in the patho-
genesis and progression of different carcinoma types. In vivo
and in vitro studies have shown that these proteins are able
to induce cell transformation [5].
Subjects
The present study included ﬁfty three patients whowere selected
from the Chest Department inpatients, Kasr Alainy Hospital.
The selected patients had either exudative pleural effusion
according to the light’s criteria [6], pleural thickening or pleural
masses that allows pleural biopsy to be performed. Patients with
transudative pleural effusion, bleeding disorders or unﬁt for
pleural biopsy procedures were excluded from the study.
The included patients were divided into 3 subgroups
according to histopathological examination of the pleural
biopsy:
 Group I: included 19 patients with benign pleural effusion.
 Group II: included 21 with MPM.
 Group III: included 13 patients with malignant pleural effu-
sions other than mesothelioma.
Methods
All included patients were subjected to written informed con-
sent, full history taking, detailed clinical examination, plain
chest X-ray, CT chest, and thoracentesis with chemical and
cytological analysis of the pleural ﬂuid samples. Pleural biopsy
was also obtained and sent for histopathological examination
to reach a ﬁnal diagnosis and to search for the presence of mes-
othelial cells in pleural biopsy. Then immunohistochemical
staining was done in the pleural biopsy specimens that showedthe presence of mesothelial cells for the detection of epidermal
growth factor receptor.
Finally chemical pleurodesis was performed for malignant
cases only, when the pleural ﬂuid drainage was less than
100 cc/day and the lung was clinically and radiologically fully
expanded.
Out of the 53 patients who formed the study population, 48
cases were diagnosed by medical thoracoscopic pleural biopsy,
one case was diagnosed by sonar guided pleural biopsy and
another one was diagnosed by Abram’s needle. Also 3 patients
underwent open thoracotomy and decortication.Histopathological examination of the pleural biopsy
All tissue samples were routinely processed, ﬁxed in 10% buf-
fered formalin, dehydrated, cleared and embedded in parafﬁn
wax according to the routine processing procedure. Two sec-
tions (5 microns thick) were prepared from each tissue parafﬁn
block. One was stained by Hematoxylin and Eosin (H&E)
staining for routine histopathologic examination and the other
sections were on charged slides and subjected to immunohisto-
chemical staining by mouse anti-EGFR.
Then all patients were classiﬁed according to the results of
the routine histopathological analysis of the pleural biopsy
into 3 subgroups as mentioned previously.
Immunohistochemical staining for detection of EGFR in pleural
biopsy
Immunohistochemical staining by labeled streptavidin–biotin
method of immunohistochemistry for EGFR by mouse anti-
EGFR clone 31G7, antibody conc. 357 lg/ml serial number
20718528L, manufacturer: Genemed biotech USA, REF: 61-
0027-2 and dilution of 1:50–1:100 for 30–60 min at room
temperature).
After deparafﬁnization and rehydration, sections were
placed in 3% hydrogen peroxide for 20 min to inactivate
endogenous peroxidase and treated by microwave at 121 C
in citrate buffer (10 mM, pH 6.0) for 10 min as an antigen
retrieval method. After cooling to room temperature for
30 min, specimens were non-speciﬁcally blocked by incubation
with normal rabbit serum for 15 min at room temperature.
Sections were incubated with the primary antibodies for one
hour at room temperature. The sections were then subjected
to a three-step labeling procedure, with the use of streptavidin
biotin complex using 3,30-diaminobenzidine as the chromogen
and the sections were faintly counterstained with Hematoxylin.
The positive control for EGFR consisted of sections from
metaplastic carcinoma of the breast known as positive for
Role of epidermal growth factor receptor in malignant pleural mesothelioma 875EGFR. Sections of the positive control were used in each run.
Pleural biopsies that exhibited either cytoplasmic or membra-
nous immunoreactivity in mesothelial cells are considered as
positive [7].
Statistical analysis
Data were statistically described in terms of mean ± standard
deviation (±SD), median and range or frequencies (number of
cases) and percentages when appropriate. Comparison of
numerical variables between the study groups was done using
Student t test for independent samples in comparing 2 groups
when normally distributed and the Mann Whitney U test for
independent samples when not normally distributed. Compar-
ison of numerical variables between more than two groups was
done using a one way analysis of variance (ANOVA) test with
posthoc multiple 2-group comparisons in normal data and the
Kruskal Wallis test with posthoc multiple 2-group compari-
sons in non-normal data. For comparing categorical data,
the Chi square (v2) test was performed. Exact test was used
instead when the expected frequency is less than 5. P values
less than 0.05 were considered statistically signiﬁcant. All sta-
tistical calculations were done using computer programs SPSS
(Statistical Package for the Social Science; SPSS Inc., Chicago,
IL, USA) version 15 for Microsoft Windows.Results
The present study included 53 patients who fulﬁlled the selection
criteria and formed the study population. According to histopa-
thological analysis of pleural biopsy specimens, the study popu-
lation was divided into 3 subgroups as previously mentioned.
There was no statistically signiﬁcant difference between the 3
study subgroups in the patients’ characteristics (Table 1).Table 1 Patient characteristics.
Study subgroups
Subgroup (I)
(n= 19)
Sex Distribution (count, % within subgroup)
Female 8 (42.1%)
Male 11 (57.9%)
Age (mean ± SD) (years) 46.53 ± 14.20
Smoking prevalence (count, % within subgroup)
Smoker 9 (47.4%)
Non smoker 10 (52.6%)
Table 2 Chemical analysis of the pleural ﬂuid among study subgro
Study subgroups
Subgroup (I) (n= 19)
Mean ± S.D
Subgroup (II) (n= 21)
Mean ± S.D
S
M
Protein (g/dl) 4.68 ± 1.16 4.79 ± 1.25
LDH (IU/L) 599.21 ± 496.13 647.30 ± 427.59 5
Sugar (g/dl) 70.37 ± 28.98 93.19 ± 28.72
* P-value <0.05 = statistically signiﬁcant.Regarding pleural ﬂuid chemical analysis, there was no sta-
tistically signiﬁcant difference between the study subgroups in
protein and LDH levels, however there was statistically signif-
icant difference in the sugar level between subgroups I (benign
pleural effusion) and II (MPM) (Table 2). There was also sta-
tistically signiﬁcant difference regarding the predominant cell
pattern in the pleural ﬂuid among the study subgroups. In sub-
group I, the predominant cell was neutrophil, while lympho-
cyte was the predominant cell in subgroups II and III.
Malignant cells were found only in 2 patients among subgroup
II (Fig. 1).
After histopathological analysis of the pleural biopsy spec-
imen, 11 out of the 19 patients of subgroup I were diagnosed as
chronic nonspeciﬁc pleurisy (57.9%), 4 patients were empyema
(21.1%), 1 patient was sarcoidosis (5.3%), 1 patient was sys-
temic lupus (5.3%) and another 2 patients were diagnosed as
tuberculous pleurisy (10.5%). subgroup III (13 patients) which
is the subgroup of malignant pleural effusions other than
mesothelioma included 2 patients diagnosed as lymphoma
(15.4%), 4 cases diagnosed as metastatic adenocarcinoma of
breast origin (30.8%) and another 7 patients were diagnosed
as metastatic adenocarcinoma of lung origin (53.8%)
(Figs. 2 and 3).
As regards the presence of mesothelial cells in the pleural
biopsy specimens among the study subgroups; mesothelial cells
were present only in 8 out of the 19 patients (42.1%) of sub-
group I, while it was present in 19 (90.5%) out of the 21
patients of subgroup II and they were present in all patients
(13 patients) of subgroup III. The difference between the study
subgroups was found to be statistically signiﬁcant with a
P-value of 0.000 (Fig. 4).
Imunnohistochemical staining for the detection of EGFR
was only done in the pleural biopsy specimens that showed
the presence of mesothelial cells during routine histopatholo-
gical analysis. Among subgroup I, 8 out of the 19 patients wereTotal (n= 53) P-value
Subgroup (II)
(n= 21)
Subgroup (III)
(n= 13)
13 (61.9%) 7 (53.8%) 28 (52.8%) 0.455
8 (38.1%) 6 (46.2%) 25 (47.2%)
55.10 ± 14.68 56.46 ± 18.02 52.36 ± 15.73 0.126
8 (38.1%) 5 (38.5%) 22 (41.5%) 0.811
13 (61.9%) 8 (61.5%) 31 (58.5%)
ups.
Total (n= 53) Mean ± S.D P-value
ubgroup (III) (n= 13)
ean ± S.D
4.52 ± 0.93 4.69 ± 1.13 0.804
81.38 ± 541.84 613.25 ± 474.19 0.918
93.38 ± 22.87 85.06 ± 29.18 0.020*
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Figure 1 The predominant cell pattern during pleural ﬂuid
cytological analysis among the study subgroups.
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Figure 2 Histopathological subtypes among subgroup I (Benign
pleural effusion) of the study population.
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Figure 3 Histopathological subtypes among subgroup III
(Malignant pleural effusions other than mesothelioma) of the
study population.
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Figure 4 Presence of mesothelial cells in the pleural biopsy
specimens among the study subgroups.
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patients. All 8 cases were positive for immunostaining by
anti-EGFR antibody. Among subgroup II, 19 out of the 21
patients were stained for the detection of EGFR. 14 (73.7%)
out of these 19 patients were stained positive (Fig. 5) while
the remaining 5 patients (26.3%) were stained negative. All
the 13 patients of subgroup III were stained for detection of
EGFR. In this subgroup only 6 (46.2%) out of the 13 patients
were stained positive while the remaining 7 patients (53.8%)
were stained negative. There was a statistically signiﬁcant dif-
ference as regards the comparison between the three study sub-
groups in the immunohistochemical staining for the detection
of EGFR with a P-value of 0.029 (Table 3).
Chemical pleurodesis was done only for patients with
malignant pleural effusion, either MPM (subgroup II) ormalignant pleural effusions other than mesothelioma (sub-
group III). Chemical pleurodesis was done for 20 out of the
21 patients forming subgroup II, because the remaining
patients did not have effusion but only pleural thickening.
Among patients who underwent chemical pleurodesis in sub-
group II, 19 cases (95%) succeeded and only 1 case (5%)
failed. Chemical pleurodesis was done to all the 13 patients
of subgroup III, among them 9 cases (69.2%) succeeded and
4 cases (30.8%) failed. There was no statistically signiﬁcant dif-
ference in the success rate of chemical pleurodesis between sub-
groups II and III (Fig. 6).
As regards the relationship between positivity of EGFR
immunostaining and characteristics of the study subgroups,
it was found that there was no statistical signiﬁcance regarding
the comparison between age, sex, smoking prevalence,
biochemical analysis of pleural ﬂuid, histopathology of the
pleural biopsy within each subgroup and EGFR
immunostaining.
Also, there was no statistically signiﬁcant difference
between pleurodesis success rate and EGFR immunostaining
in the malignant subgroups of the study population (Table 4).
Discussion
Malignant mesothelioma is an insidious neoplasm with a dis-
mal prognosis arising from the mesothelial surfaces of the
pleural and peritoneal cavities, as well as from the tunica vag-
inalis and pericardium. 80% of all cases of mesothelioma are
pleural in origin [1]. Malignant pleural mesothelioma is a
highly aggressive tumor that was previously considered to be
rare and has become a very important issue over recent years
[2].
Members of the EGFR family have frequently been impli-
cated in various forms of human cancers and serve both as
prognostic markers and as therapeutic targets. Several phe-
nomena are responsible for abnormal activation of these recep-
tors in tumors, including overexpression, ampliﬁcation and
constitutive activation of mutant receptors or autocrine
growth factor loops [4].
Clinical developments over the past decade have identiﬁed
several novel therapeutic agents which inhibit tyrosine kinase
activity, either by direct receptor inhibition or indirect
inhibition of tyrosine kinase controlled pathways [8].
Figure 5 Female patient 36 years old, presented by gradual progressive dypsnea of 3 months duration. (A) Plain chest X-ray showing
massive right side pleural effusion. (B) Axial cut of CT chest showing pleural effusion with thickening of costal and mediastinal pleura. (C)
Thoracoscopic image showing diffuse thickening of costal pleura with some nodulation. (D) Microscopic image showing epithelial type
mesothelioma (H&Ex200). (E) Microscopic image showing EGFR positive staining (immunoperoxidase, DAB · 200).
Table 3 Immunohistochemical staining for detection of EGFR in the pleural biopsy among study subgroups.
Study subgroups Total
Subgroup (I) Subgroup (II) Subgroup (III)
Immunostaining Ve Count 0 5 7 12
% within Group 0.0% 26.3% 53.8% 30.0%
+Ve Count 8 14 6 28
% within Group 100.0% 73.7% 46.2% 70.0%
Total Count 8 19 13 40
% within Group 100.0% 100.0% 100.0% 100.0%
P-value = 0.029*
* P-value <0.05 = statistically signiﬁcant.
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Figure 6 Statistical comparison of the success rate of chemical
pleurodesis between subgroups II and III of the study population.
Role of epidermal growth factor receptor in malignant pleural mesothelioma 877The aimof the current studywas to evaluate the role of epider-
mal growth factor receptor in malignant pleural mesothelioma
and to investigate its value for successful chemical pleurodesis.
As regards the sex distribution in the current study, sub-
group I (patients with benign pleural effusion) included 8
females (42.1%) and 11 males (57.9%), subgroup II (MPM)
included 13 females (61.9%) and 8 males (38.1%) and sub-
group III (patients with malignant pleural effusion other than
MPM) included 7 females (53.8%) and 6 males (46.2%). There
was no statistically signiﬁcant difference as regards sex distri-
bution between the benign and malignant subgroups of pleural
effusion. Also there was no statistically signiﬁcant difference
between the male and female distribution within each
subgroup of the study population. All subgroups were sex
matched with a P-value of 0.455.
Table 4 Relationship between success rate of chemical pleurodesis and results of EGFR immunostaining among subgroup II and III
of the study population.
EGFR immunostaining
Subgroup II Subgroup III
Ve +Ve Total Ve +Ve Total
Pleurodesis Failed Count 0 1 1 3 1 4
% within IS 0.0% 7.7% 5.6% 42.9% 16.7% 30.8%
Succeeded Count 5 12 17 4 5 9
% within IS 100.0% 92.3% 94.4% 57.1% 83.3% 69.2%
Total Count 5 13 18 7 6 13
% within IS 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
P-value 1.000 0. 559
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who studied malignant pleural effusion regarding prognostic
factors for survival and response to chemical pleurodesis in a
series of 120 cases. They found in their study population that
55% were females and 45% were males. Also Burgers et al.
[10] study about implementation of guidelines in four hospitals
for pleural drainage and pleurodesis found that females were
60% and males 40%. Also Ismail [11], studied the role of vas-
cular endothelial growth factor in the diagnosis of pleural effu-
sions of different origins and he found that males were 52.9%
in the group with infectious pleural effusion.
On the other hand Akl et al. [12], a ten-year (1998–2007)
multicenter study about the epidemiology of mesothelioma in
Egypt, found that male/female ratio was 1.35/1. Similarly Reid
et al. [13] studied the age and sex differences in malignant
mesothelioma after residential exposure to blue asbestos (cro-
cidolite) and stated that the rate is higher in male subjects than
females.
As regards the mean age in the current study population, in
subgroup I, the mean age was 46.53 years, in group II, it was
55.10 years and in group III, it was 56.46 years. There was
no statistical signiﬁcance regarding the difference in mean
age among the study subgroups with P-value 0.126.
This study agreed with Ismail [11] who found that the mean
age in infectious pleural effusion group was 49.8 years and
with Akl et al. [12] who found that the mean age in mesothe-
lioma patients was 50.78 years. This is consistent with the fact
given the latency period, which is 20 to more than 40 years
moderate asbestos exposure would probably carry risk for
the asbestos worker at the age of 55 years or older to develop
mesothelioma [14]. Also Martı´nez-Morago´n et al. [9] found
that the mean age in patients with malignant pleural effusion
was 60 years. Similarly Burgers et al. [10] found in his study
that the mean age was 57 years.
As regards smoking prevalence among the study sub-
groups, subgroup I included 10 non smokers (52.6%) and 9
smokers (47.4%), subgroup II included 13 non smokers
(61.9%) and 8 smokers (38.1%) and subgroup III included 8
non smokers (61.5%) and 5 smokers (38.5%). The difference
in the smoking prevalence between the benign and malignant
subgroups of pleural effusion was found to be statistically
insigniﬁcant. Also the difference in the smoking prevalence
within each subgroup of the study population was found to
be statistically insigniﬁcant. All study subgroups were matched
in the smoking prevalence with a P-value of 0.811.
The present study agreed with Muscat and Wynder [15]
who studied cigarette smoking, asbestos exposure and malig-nant mesothelioma. They stated that there is no association
between cigarette smoking and mesothelioma, while Soe
et al. [16] who studied malignant pleural effusion found that
82.2% of cases were either heavy smokers or ex-smokers.
Regarding pleural ﬂuid chemical analysis, in subgroup I,
the mean values of total proteins, LDH and sugar were
4.68 g/dl, 599.21 IU/L and 70.37 mg/dl respectively, in sub-
group II were 4.79 g/dl, 647.30 IU/L and 93.19 mg/dl, respec-
tively and in subgroup III were 4.52 g/dl, 581.38 IU/L and
93.38 mg/dl, respectively. There was no statistical signiﬁcance
as regards the comparison between the 3 subgroups in the
mean value of total proteins and LDH but there was statisti-
cally signiﬁcant difference as regards the comparison between
subgroups I and II in the mean value of sugar, being lower in
subgroup I than subgroup II. This could be explained on the
basis that subgroup I included 4 patients with empyema and
2 cases diagnosed as tuberculous pleural effusion.
In BTS guidelines for the investigation of a unilateral pleu-
ral effusion in adults Maskell and Butland [17] stated that the
lowest glucose concentrations are found in empyema. Also
Chernow and Sahn [18], who studied 96 patients for carcino-
matous involvement of the pleura found that the mean value
for total proteins was 3.7 g/dl and that for sugar was
120 mg/dl.
Also Gottehrer et al. [19] studied pleural ﬂuid analysis in
malignant pleural mesothelioma prognostic implications and
found that the mean values for total protein, LDH and sugar
were 4.3 g/dl, 516 IU/L and 75 mg/dl, respectively.
Regarding the predominant cell pattern during pleural ﬂuid
cytological analysis in the present study, there was statistically
signiﬁcant difference between the study subgroups with a P-
value of 0.000. This agreed with Maskell and Butland [17]
who found that polymorphonuclear cells predominate, when
the patient has an acute process affecting the pleural surfaces.
Light [20] stated that the percentage of cases in which the
cytologic study of the pleural ﬂuid establishes the diagnosis
of a malignant pleural effusion ranges from 40–87%. Also
Antony et al. [21] study for management of malignant pleural
effusions stated that the diagnostic yield of cytology for meso-
thelioma is 58%. This goes hand with hand with Ismail [11]
who found that 40% of the malignant cases had a positive
cytology for malignant cells.
According to the histopathological subtypes among sub-
group I, the present study disagreed with Ismail [11] who
found that 11 cases out of 28 (benign pleural effusion) were
diagnosed as tuberculous pleural effusion while 17 cases were
diagnosed as empyema.
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of the study population, the present study agreed with Antony
et al. [21]who stated that lung carcinomahas been themost com-
mon neoplasm, accounting for approximately 1/3 of all malig-
nant effusions with 25–52% and breast carcinoma is the
secondmost commonwith 3–27%.Lymphomas, including both
Hodgkin’s disease and non Hodgkin’s lymphoma, are also an
important cause of malignant pleural effusions with 12–22%.
According to the presence of mesothelial cells in the pleural
biopsy specimens, the low percentage (42.1%) ofmesothelial cells
in the benign subgroup of pleural effusion (subgroup I) in
comparison to the malignant subgroups (subgroup II; MPM
and subgroup III) could be explained by the study of Herbert
andGallagher [22] about pleural biopsy in the diagnosis ofmalig-
nant mesothelioma who found that in inﬂammatory conditions
the mesothelial lining was usually replaced by granulation tissue.
Also this agreed with Mutsaers [23] who studied the mesothelial
cell and found that injury to themesothelium triggers events lead-
ing to themigrationofmesothelial cells fromthe edge of the lesion
center and desquamation of cells into the serosal ﬂuid.
Regarding immunohistochemical staining for detection of EGFR
in the pleural biopsy among the study subgroups
Among subgroup I, 8 (100%) patients were stained positive for
the detection of EGFR while among subgroup II, 14 (73.7%)
out 19 patients were stained positive. This agreed with Ramael
et al. [7] who studied immuno-histochemical distribution pat-
terns of EGFR in malignant mesothelioma and non neoplastic
mesothelium and they concluded that there is strong expression
of EGFR in both malignant mesothelioma and in non neoplas-
tic pleural mesothelium. Also Ikeda et al. [24] studied EGFR
aberrations in malignant mesothelioma and found that the
expression of EGFR was not different between malignant meso-
thelioma and non neoplastic mesothelial cells. Similarly Dazzi
et al. [25] reported that 68% of mesothelioma specimens showed
EGFR overexpression and Govindan et al. [26] showed EGFR
overexpression in 11 of 19 mesothelioma specimens.
On the other hand Destro et al. [27] studied EGFR overex-
pression in malignant pleural mesothelioma and found that
EGFR immunoreactivity was documented in 34/61 (55.7%)
cases of malignant pleural mesothelioma.
Although in the present study, only 6 (46.2%) out of the 13
patients forming subgroup III were stained positive for EGFR,
Koutsionasios et al. [28] who studied the value of expression of
EGFR, telomerase and topoisomerase IIa in malignant effu-
sion smears before and after chemotherapy found positive
expression of EGFR in 69.5% of the cases.
Regarding evaluation of the success rate of chemical pleu-
rodesis among subgroups II and III of the study population,
the current study disagreed with Ak et al. [29] who evaluated
pleurodesis in follow up and treatment of malignant pleural
mesothelioma patients and found that pleurodesis succeeded
in only 62% of the patients but agreed with Antony et al.
[21] who stated that pleurodesis studies have demonstrated
clinical success rates of 80–85%.
Regarding the relationship between positivity of EGFR
immunostaining and some characteristics of the study subgroups
Among subgroup I, 8 patients were stained positive for EGFR.
These 8 patients included 2 (25%) non smokers and 6 (75%)smokers. Among subgroup II (MPM), immunostaining posi-
tive cases (14 patients) included 9 (64.3%) non smokers and
5 (35.7%) smokers, while immunostaining negative cases (5
patients) included 3 (60%) non smokers and 2 (40%) smokers.
This agreed with O’Donnell et al. [30] who studied the expres-
sion of ErbB receptors and mucins in the airways of long term
current smokers and suggested that long term current smoking
induces enhanced epidermal growth factor receptor expression
in vivo and these increases are not associated with the presence
of neutrophilic inﬂammation.
Among subgroup II, the number of immunostaining posi-
tive cases was 14 patients and included 9 (64.3%) females
and 5 (35.7%) males, while the number of immunostaining
negative cases was 5 patients which included 3 (60%) females
and 2 (40%) males. The difference between immunostaining
positive and negative cases as regards sex distribution was
found to be statistically insigniﬁcant. This agreed with Rena
et al. [31] who studied EGFR overexpression in malignant
pleural mesothelioma: Prognostic correlations showed that
there was no association recorded between EGFR positive
staining and gender.
Also among Subgroup II, the mean age of immunostaining
negative cases was 52 years, while the mean age of immuno-
staining positive cases was 54.57 years. The difference between
immunostaining negative and immunostaining positive cases
in the mean age was found to be statistically insigniﬁcant with
a P-value of 0.547. This again agreed with Rena et al. [31] who
found in his study no association recorded between EGFR
positive staining and age.
Among subgroup III, the number of immunostaining posi-
tive cases was 6 patients and included 3 females (50%) and 3
males (50%), while the number of immunostaining negative
cases were 7 patients including 4 females (57.1%) and 3 males
(42.9%). The difference between immuno-staining positive and
negative cases as regards sex distribution was found to be
statistically insigniﬁcant with a P-value of 1.000. The current
study disagreed with Hsieh et al. [32] who stated that female
sex predicted the presence of EGFR mutations in lung
adenocarcinomas, while Zheng et al. [33] stated that there
was no correlation between EGFR and sex.
As regards the relationship between smoking prevalence
and immunohistochemical staining for EGFR in subgroup
III, the number of EGFR immunostaining positive cases was
6 patients and included 3 non smokers (50%) and 3 smokers
(50%), while the number of immunostaining negative cases
was 7 patients and included 5 non smokers (71.4%) and 2
smokers (28.6%). The difference between immunostaining
positive and negative cases as regards smoking prevalence
was found to be statistically insigniﬁcant with a P-value of
0.592. In contrast Zheng et al. [33] study which was small
tumor size and limited smoking history predicts activated
EGFR in early stage non small cell lung cancer (NSCLC),
found an inverse correlation between EGFR and the degree
of tobacco smoking and Kumar et al. [34] observed that
EGFR expression was signiﬁcantly higher in current smokers
than in past smokers, who in turn had higher EGFR levels
than those who never smoked and they suggested that smoking
may contribute to increased EGFR expression, possibly
through increased hypoxia in the tumor tissue of smokers.
In subgroup III, the number of immunostaining positive
cases was 6 patients and all of them were diagnosed as meta-
static adenocarcinoma but the number of immunostaining
880 A. El-Hosainy et al.negative cases were 7 patients and included 2 cases with lym-
phoma (28.6%) and 5 cases with metastatic adenocarcinoma
(71.4%). The difference between positive and negative cases
of immunostaining regarding the histopathology of the pleural
biopsy was found to be statistically insigniﬁcant with a P-value
of 0.155.
Although the literature concerning EGFR positive NSCLC
and its response to TKI therapy is broad, the number of stud-
ies focusing on EGFR positivity in pleural involvement has
been less robust [35]. The current study agreed with Shamblin
et al. [36] who studied EGFR mutations in malignant pleural
effusions from lung cancer and found that the incidence of
EGFR positivity in malignant pleural effusion appears to
range from 24–68.7%. Also this study agreed with Courville
et al. [37] who studied pseudo-epitheliomatous hyperplasia in
cutaneous T-cell lymphoma with particular interest in epithe-
lial growth factor expression and stated that no expression of
EGF could be detected in cutaneous and nodal B-cell lympho-
mas or in a normal lymph node.
Regarding the relationship of success rate of chemical
pleurodesis and EGFR immunostaining
Among the 18 patients who underwent chemical pleurodesis in
subgroup II, the number of immunostaining positive cases was
13 patients (12 succeeded [92.3%] and 1 failed [7.7%]), but the
number of immunostaining negative cases was 5 patients and
all of them had successful chemical pleurodesis. The compari-
son between immunostaining positive and negative cases in the
success rate of chemical pleurodesis revealed no statistically
signiﬁcant difference (P-value = 1.000).
In subgroup III, 13 patients had undergone chemical pleu-
rodesis. The number of immunostaining positive cases was 6
patients (5 succeeded [83.3%] and 1 failed [16.7%]), but the
number of immunostaining negative cases was 7 patients (4
succeeded [57.1%] and 3 failed [42.9%]). As regards the com-
parison between positive and negative cases of immunostain-
ing in the success rate of chemical pleurodesis, there was no
statistically signiﬁcant difference (P-value = 0.559).
In conclusion, this study found that epidermal growth fac-
tor receptor is frequently over expressed in malignant pleural
mesothelioma samples and therefore may be used as a poten-
tial therapeutic target but there was no association between
the success rate of chemical pleurodesis and expression of
EGFR by the tumor either MPM or metastatic adenocarci-
noma because there are many factors which may affect the suc-
cess rate of chemical pleurodesis including the tumor burden.
Further studies are needed to evaluate the prognostic value
of EGFR mutation and overexpression in patients with MPM.
Conﬂict of interest
None.
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